Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

YMI024

Other · developed by Novartis Pharmaceuticals

Phase 2 Most advanced trial
NVS Developer

What is YMI024?

YMI024 is a drug name with no mechanism, target or structural information in the available source texts. It is studied in coronary artery disease.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Cardiovascular
Developer
Novartis Pharmaceuticals (NVS)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

Conditions studied

Coronary Artery Disease

More from Novartis Pharmaceuticals

Follow NVS, the company behind YMI024

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.